You are on page 1of 1

1. Med Klin (Munich). 1999 Feb 15;94(2):93-100.

[Antiphospholipid antibody syndrome].


[Article in German]
Schmidt R(1), Scheuermann EH, Viertel A, Geiger H, Scharrer I.
Author information:
(1)Medizinische Klinik IV, Johann-Wolfgang-Goethe-Universitt, Frankfurt/M.
BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies
mainly characterized by the presence of the lupus anticoagulant (LA) and
anticardiolipin antibodies (ACA).
CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the
appearance of frequent thromboses, repeated fetal losses and thrombocytopenia.
Other clinical manifestations associated with APA include migraine, chorea,
hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual
pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo
reticularis, pre-eclampsia, fetal growth retardation or catastrophic
antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions
(secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune

disorders, infectious diseases, neoplastic disorders, in association with the us
e
of certain drugs or in otherwise healthy individuals (primary antiphospholipid
antibody syndrome, PAPS).
TREATMENT: Patients with thrombosis associated with APA should receive long-term

anticoagulation therapy, whereas treatment of asymptomatic patients seems to be
not indicated, because only approximately 10% of patients with APA may develop
thrombotic complications. In patients with PAPS there is no evidence that the
prophylactic administration of immunosuppressive drugs will prevent
thromboembolic events.
PMID: 10194954 [PubMed - indexed for MEDLINE]